Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Melanoma

Treatments: Biological: Nivolumab; Biological: Ipilimumab

Study type: Observational

Funder types: Industry

Identifiers

NCT03165409

CA209-789

Details and patient eligibility

About

This study is a real-world retrospective claims analysis to assess and compare AE-related HCRU and medical costs among patients with different follow-up frequency after initiating a melanoma therapy.

Enrollment: 1,828 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Diagnosed with metastatic melanoma
• Initiated at least 1 treatment for metastatic melanoma after 2011
• Continuous enrollment in their healthcare plan for at least 6 months before and at least 6 weeks after the index date
• Patients who received at least 1 dose of study drug in CA209-067